Dihydroorotate dehydrogenase polymorphism influences the toxicity of leflunomide treatment in patients with rheumatoid arthritis.
Grabar
P Bohanec
PB
Rozman
B
B
Logar
D
D
Praprotnik
S
S
Dolzan
V
V
D000368:Aged; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000235:genetics*; D019388:Cytochrome P-450 CYP1A2 / Q000235:genetics; D000090722:Dihydroorotate Dehydrogenase; D005260:Female; D006801:Humans; D007555:Isoxazoles / Q000009:adverse effects*; D000077339:Leflunomide; D008297:Male; D008875:Middle Aged; D044925:Oxidoreductases Acting on CH-CH Group Donors / Q000235:genetics*; D011110:Polymorphism, Genetic
D018501:Antirheumatic Agents; D000090722:Dihydroorotate Dehydrogenase; D007555:Isoxazoles; C504573:CYP1A2 protein, human; D019388:Cytochrome P-450 CYP1A2; D044925:Oxidoreductases Acting on CH-CH Group Donors; D000077339:Leflunomide